The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...

AstraZeneca chief Pascal Soriot has said a deepening criminal probe into his company’s Chinese business is being taken “very ...

In the US, AstraZeneca has approximately 17,800 employees working across 17 R&D, manufacturing and commercial sites spanning ...

Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...

AstraZeneca, headquartered in Cambridge UK but globally influential, is investing $3.5 billion in the United States to expand ...

CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the ...

AstraZeneca said it plans to pump $2 billion in new investment ... The new spending will be for a research-and-development ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...

CAMBRIDGE, Britain — CAMBRIDGE, Britain — Astrazeneca PLC (AZN) on Tuesday reported third-quarter earnings of $1.43 billion. On a per-share basis, the Cambridge, Britain-based company said it had ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

Astrazeneca has recently announced 3.5 billion dollars of capital investment in the United States focused on expanding the ...